Oral and subcutaneous therapy of canine atopic dermatitis with recombinant feline interferon omega

Cytokine

Volumn 66, Issue 1, 2014, Pages 54-59

  Litzlbauer, Petra ^a   Weber, Karin ^a   Mueller, Ralf S ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Atopy; Dog; Immune response; Treatment

Indexed keywords

ATOPY; DOG; IMMUNE RESPONSE; TREATMENT;

ADMINISTRATION, ORAL; ANIMALS; CATS; DERMATITIS, ATOPIC; DOG DISEASES; DOGS; FEMALE; INJECTIONS, SUBCUTANEOUS; INTERFERON TYPE I; MALE; MASS SPECTROMETRY; RECOMBINANT PROTEINS; SUS SCROFA;

EID: 84893419374     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2013.12.001     Document Type: Article

References (58)

1. Halliwell R. Revised nomenclature for veterinary allergy. Vet Immunol Immunopathol 2006, 114:207-208.
2. Hillier A., Griffin C.E. The ACVD task force on canine atopic dermatitis (I): incidence and prevalence. Vet Immunol Immunopathol 2001, 81:147-151.
3. Olivry T., Deboer D.J., Favrot C., Jackson H.A., Mueller R.S., Nuttall T., et al. Treatment of canine atopic dermatitis: 2010 clinical practice guidelines from the International Task Force on Canine Atopic Dermatitis. Vet Dermatol 2010.
4. Borden E.C., Sen G.C., Uze G., Silverman R.H., Ransohoff R.M., Foster G.R., et al. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 2007, 6:975-990.
5. Renz H., Jujo K., Bradley K.L., Domenico J., Gelfand E.W., Leung D.Y. Enhanced IL-4 production and IL-4 receptor expression in atopic dermatitis and their modulation by interferon-gamma. J Invest Dermatol 1992, 99:403-408.
6. Reinhold U., Wehrmann W., Kukel S., Kreysel H.W. Evidence that defective interferon-gamma production in atopic dermatitis patients is due to intrinsic abnormalities. Clin Exp Immunol 1990, 79:374-379.
7. Jujo K., Renz H., Abe J., Gelfand E.W., Leung D.Y. Decreased interferon gamma and increased interleukin-4 production in atopic dermatitis promotes IgE synthesis. J Allergy Clin Immunol 1992, 90:323-331.
8. van Reijsen F.C., Bruijnzeel-Koomen C.A., Kalthoff F.S., Maggi E., Romagnani S., Westland J.K., et al. Skin-derived aeroallergen-specific T-cell clones of Th2 phenotype in patients with atopic dermatitis. J Allergy Clin Immunol 1992, 90:184-193.
9. Leung D.Y.M. Pathogenesis of atopic dermatitis. J Allergy Clin Immunol 1999, 104:S99-S108.
10. Mosmann T.R., Cherwinski H., Bond M.W., Giedlin M.A., Coffman R.L. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986, 136:2348-2357.
11. Pene J., Rousset F., Briere F., Chretien I., Bonnefoy J.Y., Spits H., et al. IgE production by normal human lymphocytes is induced by interleukin 4 and suppressed by interferons gamma and alpha and prostaglandin E2. Proc Natl Acad Sci USA 1988, 85:6880-6884.
12. Hayashiya S., Tani K., Morimoto M., Hayashi T., Hayasaki M., Nomura T., et al. Expression of T helper 1 and T helper 2 cytokine mRNAs in freshly isolated peripheral blood mononuclear cells from dogs with atopic dermatitis. J Vet Med A Physiol Pathol Clin Med 2002, 49:27-31.
13. Olivry T., Dean G.A., Tompkins M.B., Dow J.L., Moore P.F. Toward a canine model of atopic dermatitis: amplification of cytokine-gene transcripts in the skin of atopic dogs. Exp Dermatol 1999, 8:204-211.
14. Nuttall T.J., Knight P.A., McAleese S.M., Lamb J.R., Hill P.B. T-helper 1, T-helper 2 and immunosuppressive cytokines in canine atopic dermatitis. Vet Immunol Immunopathol 2002, 87:379-384.
15. Iwasaki T., Kagawa Y., Park S.J., Kanazawa N., Momoi Y., Tanikawa H., et al. Effect of recombinant canine IFNγ on canine atopic dermatitis evaluated by clinical signs, histopathology and expression of Th1/Th2 cytokine mRNA. Vet Dermatol 2004, 15:1.
16. Iwasaki T., Hasegawa A. A randomized comparative clinical trial of recombinant canine interferon-gamma (KT-100) in atopic dogs using antihistamine as control. Vet Dermatol 2006, 17:195-200.
17. Yasukawa K., Saito S., Kubo T., Shibasaki Y., Yamaoka K., Hachimura H., et al. Low-dose recombinant canine interferon-gamma for treatment of canine atopic dermatitis: an open randomized comparative trial of two doses. Vet Dermatol 2010, 21:42-49.
18. Hasegawa A., Sakurai T., Iwasaki T. A placebo-controlled, double-blinded study of recombinant interferon-gamma in dogs with atopic dermatitis. Vet Dermatol 2004, 15:1.
19. Carlotti D.N., Boulet M., Ducret J., Machicote G., Jasmin P., Reme C.A., et al. The use of recombinant omega interferon therapy in canine atopic dermatitis: a double-blind controlled study. Vet Dermatol 2009, 20:405-411.
20. Steffan J., Favrot C., Mueller R. A systematic review and meta-analysis of the efficacy and safety of cyclosporin for the treatment of atopic dermatitis in dogs. Vet Dermatol 2006, 17:3-16.
21. Zeidner N.S., Myles M.H., Mathiason-DuBard C.K., Dreitz M.J., Mullins J.I., Hoover E.A. Alpha interferon (2b) in combination with zidovudine for the treatment of presymptomatic feline leukemia virus-induced immunodeficiency syndrome. Antimicrob Agents Chemother 1990, 34:1749-1756.
22. Pedretti E., Passeri B., Amadori M., Isola P., Di Pede P., Telera A., et al. Low-dose interferon-alpha treatment for feline immunodeficiency virus infection. Vet Immunol Immunopathol 2006, 109:245-254.
23. Cantell K., Pyhala L. Circulating interferon in rabbits after administration of human interferon by different routes. J Gen Virol 1973, 20:97-104.
24. Wills R.J., Spiegel H.E., Soike K.F. Pharmacokinetics of recombinant alpha A interferon following I.V. infusion and bolus, I.M., and P.O. administrations to African green monkeys. J Interferon Res 1984, 4:399-409.
25. Gibson D.M., Cotler S., Spiegel H.E., Colburn W.A. Pharmacokinetics of recombinant leukocyte A interferon following various routes and modes of administration to the dog. J Interferon Res 1985, 5:403-408.
26. Eid P., Meritet J.F., Maury C., Lasfar A., Weill D., Tovey M.G. Oromucosal interferon therapy: pharmacokinetics and pharmacodynamics. J Interferon Cytokine Res 1999, 19:157-169.
27. Beilharz M.W., McDonald W., Watson M.W., Heng J., McGeachie J., Lawson C.M. Low-dose oral type I interferons reduce early virus replication of murine cytomegalovirus in vivo. J Interferon Cytokine Res 1997, 17:625-630.
28. Gilger B.C., Rose P.D., Davidson M.G., Roberts S.M., Miller T. Low-dose oral administration of interferon-alpha for the treatment of immune-mediated keratoconjunctivitis sicca in dogs. J Interferon Cytokine Res 1999, 19:901-905.
29. Satoh Y., Kasama K., Kuwabara M., Yimin H.Y., Diao H., Nakajima, et al. Suppression of late asthmatic response by low-dose oral administration of interferon-beta in the guinea pig model of asthma. J Interferon Cytokine Res 1999, 19:887-894.
30. Tovey M.G., Maury C. Oromucosal interferon therapy: marked antiviral and antitumor activity. J Interferon Cytokine Res 1999, 19:145-155.
31. Nakajima A., Sokawa Y. Induction of blood 2',5'-oligoadenylate synthetase activity in mice by gastric administration of ovine IFN-tau. J Interferon Cytokine Res 2002, 22:397-402.
32. Cummins J.M., Beilharz M.W., Krakowka S. Oral use of interferon. J Interferon Cytokine Res 1999, 19:853-857.
33. Tompkins W.A. Immunomodulation and therapeutic effects of the oral use of interferon-alpha: mechanism of action. J Interferon Cytokine Res 1999, 19:817-828.
34. Cummins J.M., Krakowka G.S., Thompson C.G. Systemic effects of interferons after oral administration in animals and humans. Am J Vet Res 2005, 66:164-176.
35. Schellekens H., Geelen G., Meritet J.F., Maury C., Tovey M.G. Oromucosal interferon therapy: relationship between antiviral activity and viral load. J Interferon Cytokine Res 2001, 21:575-581.
36. Moore B.R., Krakowka S., Cummins J.M., Robertson J.T. Changes in airway inflammatory cell populations in standardbred racehorses after interferon-alpha administration. Vet Immunol Immunopathol 1996, 49:347-358.
37. Olivry T., Marsella R., Iwasaki T., Mueller R. Validation of CADESI-03, a severity scale for clinical trials enrolling dogs with atopic dermatitis. Vet Dermatol 2007, 18:78-86.
38. Olivry T., Mueller R., Nuttall T., Favrot C., Prelaud P. Determination of CADESI-03 thresholds for increasing severity levels of canine atopic dermatitis. Vet Dermatol 2008, 19:115-119.
39. Rybnicek J., Lau-Gillard P.J., Harvey R., Hill P.B. Further validation of a pruritus severity scale for use in dogs. Vet Dermatol 2009, 20:115-122.
40. Mueller R.S., Fieseler K.V., Fettman M.J., Zabel S., Rosychuk R.A., Ogilvie G.K., et al. Effect of omega-3 fatty acids on canine atopic dermatitis. J Small Anim Pract 2004, 45:293-297.
41. Favrot C., Linek M., Mueller R., Zini E. Development of a questionnaire to assess the impact of atopic dermatitis on health-related quality of life of affected dogs and their owners. Vet Dermatol 2010, 21:63-69.
42. Miyazawa H., Saitoh S., Kumagai T., Yamanaka T., Yasuda S., Tsunetsugu-Yokota Y., et al. Specific IgG to gelatin in children with systemic immediate- and nonimmediate-type reactions to measles, mumps and rubella vaccines. Vaccine 1999, 17:2176-2180.
43. Michalski W.P., O'Rourke D., Bagust T.J. Chicken anaemia virus antibody ELISA: problems with non-specific reactions. Avian Pathol: J WVPA 1996, 25:245-254.
44. Wichmann O., Stark K., Shu P.Y., Niedrig M., Frank C., Huang J.H., et al. Clinical features and pitfalls in the laboratory diagnosis of dengue in travellers. BMC Infect Dis 2006, 6:120.
45. van Vuren P.J., Paweska J.T. Comparison of enzyme-linked immunosorbent assay-based techniques for the detection of antibody to Rift Valley fever virus in thermochemically inactivated sheep sera. Vector Borne Zoonotic Dis 2010, 10:697-699.
46. Reidy L., Walls H.C., Steele B.W. Crossreactivity of bupropion metabolite with enzyme-linked immunosorbent assays designed to detect amphetamine in urine. Ther Drug Monit 2011, 33:366-368.
47. Pathak S., Palan U. Immunology: essential and fundamental 2005, Science Publishers Inc., Enfield, NH, USA. 2nd ed.
48. Arkwright P.D., Patel L., Moran A., Haeney M.R., Ewing C.I., David T.J. Atopic eczema is associated with delayed maturation of the antibody response to pneumococcal vaccine. Clin Exp Immunol 2000, 122:16-19.
49. Scott J.E., ElKhal A., Freyschmidt E.J., MacArthur D.H., McDonald D., Howell M.D., et al. Impaired immune response to vaccinia virus inoculated at the site of cutaneous allergic inflammation. J Allergy Clin Immunol 2007, 120:1382-1388.
50. Hamid Q., Boguniewicz M., Leung D.Y. Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. J Clin Invest 1994, 94:870-876.
51. Hamid Q., Naseer T., Minshall E.M., Song Y.L., Boguniewicz M., Leung D.Y. In vivo expression of IL-12 and IL-13 in atopic dermatitis. J Allergy Clin Immunol 1996, 98:225-231.
52. Grewe M., Czech W., Morita A., Werfel T., Klammer M., Kapp A., et al. Human eosinophils produce biologically active IL-12: implications for control of T cell responses. J Immunol 1998, 161:415-420.
53. Olivry T., Deboer D.J., Prelaud P., Bensignor E. Food for thought: pondering the relationship between canine atopic dermatitis and cutaneous adverse food reactions. Vet Dermatol 2007, 18:390-391.
54. Jeffers J.G., Shanley K.J., Meyer E.K. Diagnostic testing of dogs for food hypersensitivity. J Am Vet Med Assoc 1991, 198:245-250.
55. Hall E.J. Gastrointestinal aspects of food allergy: a review. J Small Anim Pract 1994, 35:145-152.
56. Harvey R.G. Food allergy and dietary intolerance in dogs: a report of 25 cases. J Small Anim Pract 1993, 34:175-179.
57. Rosser E.J. Diagnosis of food allergy in dogs. J Am Vet Med Assoc 1993, 203:259-262.
58. Veenhof E.Z., Knol E.F., Schlotter Y.M., Vernooij J.C., Rutten V.P., Willemse T. Characterisation of T cell phenotypes, cytokines and transcription factors in the skin of dogs with cutaneous adverse food reactions. Vet J 2011, 187:320-324.